Oct 23, 2018 - Three biotech stocks are scheduled to release their third-quarter results on Oct 24. Let's take a look at how these companies are poised ahead of their earnings release.
Oct 22, 2018 - Novartis (NVS) beats sales estimates in Q3, driven by Cosentyx and Entresto, while earnings came in line. The company plans to acquire Endocyte to broaden its oncology pipeline.
Oct 22, 2018 - We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.
Oct 22, 2018 - Novartis paid $2.1 billion to acquire Endocyte for its radioligand therapy candidate PSMA-617.The acquisition of Endocyte was a smart strategic move because it builds upon a prior acquisition that als
Oct 19, 2018 - OptimizeRx has acquired CareSpeak Communications for up to $8.5 million in total consideration.CareSpeak has developed a mobile-first patient communication system.OPRX has achieved rapid growth in rec
Oct 19, 2018 - The biotech stocks plunge along with the broader market, as the smallcap and midcap biotech stocks retreat -17%.The larger cap biotechs and pharma are performing relatively much better.The performance
Oct 18, 2018 - Novartis AG (NYSE:NVS) Q3 2018 Earnings Conference Call October 18, 2018 8:00 AM ET Executives Samir Shah – Global Head-Investor Relations Vas Narasimhan – Chief Executive Officer Harry Kirsch – Chief
Oct 18, 2018 - Novartis to Buy Biopharmaceutical Company Endocyte for $2.1 Billion, Stocks: NVS,ECYT, release date:Oct 18, 2018
Oct 18, 2018 - The following slide deck was published by Novartis AG in conjunction with their 2018 Q3 earnings call.
Oct 18, 2018 - Novartis (NVS) announces encouraging five-year data from late-stage studies on Cosentyx for psoriatic arthritis and ankylosing spondylitis indications.